Menopause Home > Minivelle Warnings and Precautions

Specific Precautions and Warnings for Minivelle

Some of the warnings and precautions to be aware of prior to using Minivelle include the following:
  • For women who still have a uterus, using Minivelle alone (without a progestin) increases the risk for endometrial cancer (cancer of the lining of the uterus). Women who still have a uterus should use this drug with a progestin medication.
  • Let your healthcare provider know if you have abnormal vaginal bleeding, such as very heavy bleeding or bleeding between periods, while using Minivelle, as this may be a sign of precancerous or cancerous changes in the uterus. Your healthcare provider can perform the necessary tests to rule out cancer.
  • When possible, Minivelle should be stopped four to six weeks before many surgeries to help prevent blood clots.
  • Estrogen drugs, such as Minivelle, used with or without a progestin may increase the risk of breast cancer. Proper screening and monitoring, as determined by your healthcare provider, such as yearly mammograms and monthly self breast exams, is recommended.
  • Estrogen drugs used with or without a progestin seem to increase the risk of dementia. In no case should Minivelle be used to prevent or treat dementia; it is not effective for this use.
  • Women who take estrogen have an increased risk for gallbladder disease.
  • Let your healthcare provider know right away if you notice any vision changes. This can signal a blood clot in the retina, a possible side effect of Minivelle.
  • If you have had jaundice (yellowing of the whites of the eyes or skin) due to estrogens or pregnancy in the past, Minivelle could cause similar problems to recur. If this happens, your healthcare provider will probably advise you to stop using this drug.
  • If you have an underactive thyroid (hypothyroidism), Minivelle may increase your body's requirement for thyroid hormones. Your healthcare provider should monitor you and adjust the dose of your thyroid medication as necessary.
  • Minivelle can cause fluid retention. This can cause problems for people with congestive heart failure (CHF) or kidney problems.
  • Minivelle should be used with caution in people who have low calcium levels in the blood (known medically as hypocalcemia).
  • It is not clear if Minivelle increases the risk of ovarian cancer. Some studies have shown an increased risk, while others have not.
  • This medication can make endometriosis symptoms worse.
  • Minivelle does pass through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to using the drug (see Minivelle and Breastfeeding).
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.